{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:03:37Z","timestamp":1793318617634,"version":"4.5.0"},"reference-count":117,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T00:00:00Z","timestamp":1699747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. Surgical management, including hepatic resection, liver transplantation, and ablation, offers the greatest potential for a curative approach. This review aims to discuss recent advancements in HCC surgery and identify unresolved issues in the field. Treatment selection relies on the BCLC staging system, with surgical therapies primarily recommended for early-stage disease. Recent studies have shown that patients previously considered unresectable, such as those with portal vein tumor thrombus and uncomplicated portal hypertension, may benefit from hepatic resection. Minimally invasive surgery and improved visualization techniques are also explored, alongside new techniques for optimizing future liver remnant, ex vivo resection, and advancements in hemorrhage control. Liver transplantation criteria, particularly the long-standing Milan criteria, are critically examined. Alternative criteria proposed and tested in specific regions are presented. In the context of organ shortage, bridging therapy plays a critical role in preventing tumor progression and maintaining patients eligible for transplantation. Lastly, we explore emerging ablation modalities, comparing them with the current standard, radiofrequency ablation. In conclusion, this comprehensive review provides insights into recent trends and future prospects in the surgical management of HCC, highlighting areas that require further investigation.<\/jats:p>","DOI":"10.3390\/cancers15225378","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T02:46:47Z","timestamp":1699843607000},"page":"5378","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Current Trends in Surgical Management of Hepatocellular Carcinoma"],"prefix":"10.3390","volume":"15","author":[{"given":"Isabella","family":"Angeli-Pahim","sequence":"first","affiliation":[{"name":"Department of Surgery, College of Medicine, University of Florida, Gainesville, FL 32608, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Chambers","sequence":"additional","affiliation":[{"name":"Department of Surgery, College of Medicine, University of Florida, Gainesville, FL 32608, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Duarte","sequence":"additional","affiliation":[{"name":"Department of Surgery, College of Medicine, University of Florida, Gainesville, FL 32608, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Zarrinpar","sequence":"additional","affiliation":[{"name":"Department of Surgery, College of Medicine, University of Florida, Gainesville, FL 32608, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","article-title":"Global, regional and national burden of primary liver cancer by subtype","volume":"161","author":"Rumgay","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_4","unstructured":"European Association for the Study of the Liver (2018). Electronic address: Easloffice@easloffice.eu; European Association for the Study of the Liver EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol., 69, 182\u2013236."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ctrv.2018.11.002","article-title":"Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence","volume":"72","author":"Raoul","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3390\/curroncol30020190","article-title":"Stereotactic body radiotherapy for hepatocellular carcinoma: A brief overview","volume":"30","author":"Matsuo","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jhep.2011.07.012","article-title":"Radioembolization for hepatocellular carcinoma","volume":"56","author":"Sangro","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2214\/AJR.19.22098","article-title":"Locoregional Therapies in the Treatment of 3- to 5-cm Hepatocellular Carcinoma: Critical Review of the Literature","volume":"215","author":"Young","year":"2020","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zhang, H., Zhang, W., Jiang, L., and Chen, Y. (2022). Recent advances in systemic therapy for hepatocellular carcinoma. Biomark. Res., 10.","DOI":"10.1186\/s40364-021-00350-4"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Wang, S., Wang, Y., Yu, J., Wu, H., and Zhou, Y. (2022). Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Cancers, 14.","DOI":"10.3390\/cancers14225525"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"RESORCE Investigators Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma","volume":"379","author":"Meyer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"REACH-2 study investigators Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12943-019-1047-6","article-title":"Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: Challenges and opportunities","volume":"18","author":"Lu","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): A randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1200\/JCO.22.00620","article-title":"Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia with Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial","volume":"41","author":"Qin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/onco.13819","article-title":"FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib","volume":"26","author":"Saung","year":"2021","journal-title":"Oncologist"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The checkmate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"IMbrave150 Investigators Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Sinner, F., Pinter, M., Scheiner, B., Ettrich, T.J., Sturm, N., Gonzalez-Carmona, M.A., Waidmann, O., Finkelmeier, F., Himmelsbach, V., and De Toni, E.N. (2022). Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience. Cancers, 14.","DOI":"10.3390\/cancers14235966"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): A multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"Kelley","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Abou-Alfa, G.K., Lau, G., Kudo, M., Chan, S.L., Kelley, R.K., Furuse, J., Sukeepaisarnjaroen, W., Kang, Y.-K., Van Dao, T., and De Toni, E.N. (2022). Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid.","DOI":"10.1056\/EVIDoa2100070"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: Randomized expansion of a phase I\/II study","volume":"39","author":"Kelley","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"CARES-310 Study Group Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): A randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000514313","article-title":"Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations","volume":"10","author":"Zhu","year":"2021","journal-title":"Liver Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s12328-022-01644-2","article-title":"A case of conversion hepatectomy for huge hepatocellular carcinoma with adrenal metastasis and vascular invasion after atezolizumab-bevacizumab treatment","volume":"15","author":"Hoshino","year":"2022","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12328-022-01744-z","article-title":"Complete tumor necrosis confirmed by conversion hepatectomy after atezolizumab-bevacizumab treatment for advanced-stage hepatocellular carcinoma with lung metastasis","volume":"16","author":"Fukunaga","year":"2023","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Okuno, M., Ishii, T., Ichida, A., Soyama, A., Takemura, N., Hirono, S., Eguchi, S., Hasegawa, K., Sasaki, Y., and Uemura, K. (2023). Protocol of the RACB study: A multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11302-6"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ozer, M., Goksu, S.Y., Akagunduz, B., George, A., and Sahin, I. (2023). Adoptive cell therapy in hepatocellular carcinoma: A review of clinical trials. Cancers, 15.","DOI":"10.3390\/cancers15061808"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Jeng, L.-B., Liao, L.-Y., Shih, F.-Y., and Teng, C.-F. (2022). Dendritic-Cell-Vaccine-Based Immunotherapy for Hepatocellular Carcinoma: Clinical Trials and Recent Preclinical Studies. Cancers, 14.","DOI":"10.3390\/cancers14184380"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1172292","DOI":"10.3389\/fonc.2023.1172292","article-title":"Recent advances in oncolytic virus therapy for hepatocellular carcinoma","volume":"13","author":"Zhu","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000503685","article-title":"Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition)","volume":"9","author":"Cheng","year":"2020","journal-title":"Liver Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jhep.2016.05.044","article-title":"Liver Cancer Study Group of Japan Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion","volume":"65","author":"Kokudo","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e3015","DOI":"10.1097\/MD.0000000000003015","article-title":"Multimodality Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score Analysis","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/hep.27431","article-title":"Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta-analysis","volume":"61","author":"Berzigotti","year":"2015","journal-title":"Hepatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1007\/s00464-017-5930-1","article-title":"Benefits of laparoscopic liver resection in patients with hepatocellular carcinoma and portal hypertension: A case-matched study","volume":"32","author":"Molina","year":"2018","journal-title":"Surg. Endosc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.4254\/wjh.v13.i11.1629","article-title":"Current strategies to induce liver remnant hypertrophy before major liver resection","volume":"13","author":"Gaillard","year":"2021","journal-title":"World J. Hepatol."},{"key":"ref_41","first-page":"238","article-title":"Post-hepatectomy liver failure","volume":"3","author":"Kauffmann","year":"2014","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1477-2574.2012.00557.x","article-title":"Americas Hepato-Pancreato-Biliary Association; Society of Surgical Oncology; Society for Surgery of the Alimentary Tract Selection for hepatic resection of colorectal liver metastases: Expert consensus statement","volume":"15","author":"Adams","year":"2013","journal-title":"HPB"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00270-012-0440-y","article-title":"Portal vein embolization before liver resection: A systematic review","volume":"36","author":"Bipat","year":"2013","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Buechter, M., and Gerken, G. (2022). Liver Function-How to Screen and to Diagnose: Insights from Personal Experiences, Controlled Clinical Studies and Future Perspectives. J. Pers. Med., 12.","DOI":"10.3390\/jpm12101657"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0399-8320(08)73994-0","article-title":"Transient elastography (FibroScan)","volume":"32","author":"Vergniol","year":"2008","journal-title":"Gastroenterol. Clin. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1111\/j.1440-1746.2010.06437.x","article-title":"Transient elastography","volume":"25","author":"Wong","year":"2010","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7236","DOI":"10.3748\/wjg.v22.i32.7236","article-title":"Transient elastography (FibroScan(\u00ae)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease\u2014Where do we stand?","volume":"22","author":"Mikolasevic","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.diii.2013.01.022","article-title":"Ultrasound elastography: Principles and techniques","volume":"94","author":"Gennisson","year":"2013","journal-title":"Diagn. Interv. Imaging"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"11567","DOI":"10.3748\/wjg.v21.i41.11567","article-title":"Non-invasive diagnosis of liver fibrosis and cirrhosis","volume":"21","author":"Lurie","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1148\/rg.296095512","article-title":"MR imaging of liver fibrosis: Current state of the art","volume":"29","author":"Faria","year":"2009","journal-title":"Radiographics"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1148\/rg.296095508","article-title":"Cirrhosis and lesion characterization at MR imaging","volume":"29","author":"Hussain","year":"2009","journal-title":"Radiographics"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1499-3872(14)60267-8","article-title":"Advances in preoperative assessment of liver function","volume":"13","author":"Ge","year":"2014","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0039-6109(03)00224-X","article-title":"Preoperative assessment of liver function","volume":"84","author":"Schneider","year":"2004","journal-title":"Surg. Clin. N. Am."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4254\/wjh.v8.i7.355","article-title":"Indocyanine green kinetics to assess liver function: Ready for a clinical dynamic assessment in major liver surgery?","volume":"8","author":"Mazza","year":"2016","journal-title":"World J. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jhep.2010.07.047","article-title":"Transporters involved in the hepatic uptake of (99m)Tc-mebrofenin and indocyanine green","volume":"54","author":"Heger","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jss.2015.03.093","article-title":"A rapid, reproducible, noninvasive predictor of liver graft survival","volume":"197","author":"Zarrinpar","year":"2015","journal-title":"J. Surg. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/17434440.2016.1126178","article-title":"Portable device for the analysis of liver function: A boon to liver surgery and critical care","volume":"13","author":"Mobley","year":"2016","journal-title":"Expert. Rev. Med. Devices"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/hep.1840160311","article-title":"Localization of cytochrome P-450 gene expression in normal and diseased human liver by in situ hybridization of wax-embedded archival material","volume":"16","author":"Palmer","year":"1992","journal-title":"Hepatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/SLA.0b013e3181ad85b5","article-title":"Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity","volume":"250","author":"Stockmann","year":"2009","journal-title":"Ann. Surg."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000493573","article-title":"Liver maximum capacity: A novel test to accurately diagnose different stages of liver fibrosis","volume":"100","author":"Buechter","year":"2019","journal-title":"Digestion"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.12998\/wjcc.v7.i22.3734","article-title":"End-stage liver disease score and future liver remnant volume predict post-hepatectomy liver failure in hepatocellular carcinoma","volume":"7","author":"Kong","year":"2019","journal-title":"World J. Clin. Cases"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.3892\/ol.2017.5919","article-title":"Integration of Child-Pugh score with future liver remnant yields improved prediction of liver dysfunction risk for HBV-related hepatocellular carcinoma following hepatic resection","volume":"13","author":"Zou","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10238-015-0388-8","article-title":"Hyaluronic acid concentration in liver diseases","volume":"16","author":"Gudowska","year":"2016","journal-title":"Clin. Exp. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1365-2168.2001.01658.x","article-title":"Portal vein embolization: Rationale, technique and future prospects","volume":"88","author":"Abdalla","year":"2001","journal-title":"Br. J. Surg."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ijsu.2014.12.008","article-title":"ALPPS: Challenging the concept of unresectability--a systematic review","volume":"13","author":"Bertens","year":"2015","journal-title":"Int. J. Surg."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/SLA.0b013e31815f6e5b","article-title":"Preoperative portal vein embolization for major liver resection: A meta-analysis","volume":"247","author":"Abulkhir","year":"2008","journal-title":"Ann. Surg."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/SLA.0000000000003433","article-title":"ALPPS Versus Portal Vein Embolization for Hepatitis-related Hepatocellular Carcinoma: A Changing Paradigm in Modulation of Future Liver Remnant Before Major Hepatectomy","volume":"273","author":"Chan","year":"2021","journal-title":"Ann. Surg."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijscr.2019.03.060","article-title":"Associating liver partition and portal vein ligation for staged hepatectomy in Qatar: Initial experience with two case series and review of the literature","volume":"58","author":"Sulieman","year":"2019","journal-title":"Int. J. Surg. Case Rep."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Cioffi, L., Belli, G., Izzo, F., Fantini, C., D\u2019Agostino, A., Russo, G., Patrone, R., Granata, V., and Belli, A. (2023). Minimally Invasive ALPPS Procedure: A Review of Feasibility and Short-Term Outcomes. Cancers, 15.","DOI":"10.3390\/cancers15061700"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/SLA.0000000000000949","article-title":"ALPPS: From human to mice highlighting accelerated and novel mechanisms of liver regeneration","volume":"260","author":"Schlegel","year":"2014","journal-title":"Ann. Surg."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Chen, H., Wang, X., Zhu, W., Li, Y., Yu, Z., Li, H., Yang, Y., Zhu, S., Chen, X., and Wang, G. (2022). Application of associating liver partition and portal vein ligation for staged hepatectomy for initially unresectable hepatocellular carcinoma. BMC Surg., 22.","DOI":"10.1186\/s12893-022-01848-w"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s13304-022-01277-7","article-title":"Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for advanced hepatocellular carcinoma with macrovascular invasion","volume":"74","author":"Berardi","year":"2022","journal-title":"Updates Surg."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.1007\/s00464-023-09937-4","article-title":"ALPPS Italian Registry Evolution of minimally invasive techniques and surgical outcomes of ALPPS in Italy: A comprehensive trend analysis over 10 years from a national prospective registry","volume":"37","author":"Serenari","year":"2023","journal-title":"Surg. Endosc."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/archsurg.2009.229","article-title":"Laparoscopic liver resection for malignant and benign lesions: Ten-year Norwegian single-center experience","volume":"145","author":"Kazaryan","year":"2010","journal-title":"Arch. Surg."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/SLA.0000000000002072","article-title":"Pure laparoscopic versus open right hepatectomy for hepatocellular carcinoma in patients with cirrhosis: A propensity score matched analysis","volume":"265","author":"Yoon","year":"2017","journal-title":"Ann. Surg."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"106961","DOI":"10.1016\/j.ijsu.2022.106961","article-title":"Hemihepatic versus total hepatic inflow occlusion for laparoscopic hepatectomy: A randomized controlled trial","volume":"107","author":"Peng","year":"2022","journal-title":"Int. J. Surg."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00464-018-6431-6","article-title":"Meta-analysis of short- and long-term outcomes after pure laparoscopic versus open liver surgery in hepatocellular carcinoma patients","volume":"33","author":"Witowski","year":"2019","journal-title":"Surg. Endosc."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.suronc.2018.10.005","article-title":"Minimal-invasive versus open hepatectomy for hepatocellular carcinoma: Comparison of postoperative outcomes and long-term survivals using propensity score matching analysis","volume":"27","author":"Andreou","year":"2018","journal-title":"Surg. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1089\/lap.2017.0518","article-title":"Laparoscopic versus open hepatic resection for solitary hepatocellular carcinoma less than 5\u2009cm in cirrhotic patients: A randomized controlled study","volume":"28","author":"Shawky","year":"2018","journal-title":"J. Laparoendosc. Adv. Surg. Tech. A"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1245\/s10434-020-08444-3","article-title":"Minimally Invasive Versus Open Liver Resection for Hepatocellular Carcinoma in the Setting of Portal Vein Hypertension: Results of an International Multi-institutional Analysis","volume":"27","author":"Ruzzenente","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"zrac166","DOI":"10.1093\/bjsopen\/zrac166","article-title":"Asia-Pacific multicentre randomized trial of laparoscopic versus open major hepatectomy for hepatocellular carcinoma (AP-LAPO trial)","volume":"7","author":"Ng","year":"2023","journal-title":"BJS Open."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Wang, X.-B., Lin, J.-M., Chen, Y.-P., and Ye, X.-X. (2023). Surgical site wound infection and pain after laparoscopic repeat hepatectomy for recurrent hepatocellular carcinoma. Int. Wound J.","DOI":"10.1111\/iwj.14206"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Zhang, L., Yuan, Q., Xu, Y., and Wang, W. (2020). Comparative clinical outcomes of robot-assisted liver resection versus laparoscopic liver resection: A meta-analysis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0240593"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.hpb.2019.11.006","article-title":"Safety and feasibility of laparoscopic liver resection in patients with a history of abdominal surgeries","volume":"22","author":"Wabitsch","year":"2020","journal-title":"HPB"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1007\/s00464-021-08572-1","article-title":"Safety and feasibility of robotic liver resection after previous abdominal surgeries","volume":"36","author":"Frisch","year":"2022","journal-title":"Surg. Endosc."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.hpb.2020.06.006","article-title":"Identification of liver lesions using fluorescence imaging: Comparison of methods for administering indocyanine green","volume":"23","author":"Kobayashi","year":"2021","journal-title":"HPB"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1002\/cncr.24291","article-title":"Real-time identification of liver cancers by using indocyanine green fluorescent imaging","volume":"115","author":"Ishizawa","year":"2009","journal-title":"Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/XCS.0000000000000553","article-title":"Low vs Standard-Dose Indocyanine Green in the Identification of Biliary Anatomy Using Near-Infrared Fluorescence Imaging: A Multicenter Randomized Controlled Trial","volume":"236","author":"Ladd","year":"2023","journal-title":"J. Am. Coll. Surg."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jviscsurg.2014.05.006","article-title":"Long-term consequences of bile duct injury after cholecystectomy","volume":"151","author":"Barbier","year":"2014","journal-title":"J. Visc. Surg."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s12072-020-10052-y","article-title":"Consensus recommendations of three-dimensional visualization for diagnosis and management of liver diseases","volume":"14","author":"Fang","year":"2020","journal-title":"Hepatol. Int."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/XCS.0000000000000472","article-title":"Perioperative and Disease-Free Survival Outcomes after Hepatectomy for Centrally Located Hepatocellular Carcinoma Guided by Augmented Reality and Indocyanine Green Fluorescence Imaging: A Single-Center Experience","volume":"236","author":"Zhu","year":"2023","journal-title":"J. Am. Coll. Surg."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"663236","DOI":"10.3389\/fonc.2021.663236","article-title":"Augmented reality navigation for stereoscopic laparoscopic anatomical hepatectomy of primary liver cancer: Preliminary experience","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.surg.2020.05.036","article-title":"Outcomes of ex vivo liver resection and autotransplantation: A systematic review and meta-analysis","volume":"168","author":"Zawistowski","year":"2020","journal-title":"Surgery"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1007\/s11605-019-04253-6","article-title":"Three Possible Variations in Ex Vivo Hepatectomy: Achieving R0 Resection by Auto-transplantation","volume":"23","author":"Levi","year":"2019","journal-title":"J. Gastrointest. Surg."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1097\/01.sla.0000124387.87757.eb","article-title":"Combined resection of the liver and inferior vena cava for hepatic malignancy","volume":"239","author":"Hemming","year":"2004","journal-title":"Ann. Surg."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/BF01262775","article-title":"Ex situ operation on the liver. A new possibility in liver surgery","volume":"373","author":"Pichlmayr","year":"1988","journal-title":"Langenbecks Arch. Chir."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/SLA.0000000000005640","article-title":"Ex vivo liver resection and autotransplantation: Should it be used more frequently?","volume":"276","author":"Weiner","year":"2022","journal-title":"Ann. Surg."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijid.2018.11.016","article-title":"Ex vivo liver resection and autotransplantation versus allotransplantation for end-stage hepatic alveolar echinococcosis","volume":"79","author":"Shen","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/cid\/ciac195","article-title":"Evaluating the Benefits and Risks of Ex Vivo Liver Resection and Autotransplantation in Treating Hepatic End-stage Alveolar Echinococcosis","volume":"75","author":"Qiu","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/njs.NJS_4_18","article-title":"Ex situ Liver Resection and Partial Liver Autotransplantation for Advanced Cholangiocarcinoma","volume":"25","author":"Ozsoy","year":"2019","journal-title":"Niger. J. Surg."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/00365521.2022.2147802","article-title":"Intermittent Pringle maneuver combined with controlled low Central venous pressure prolongs hepatic hilum occlusion time in patients with hepatocellular carcinoma complicated by post hepatitis B cirrhosis: A randomized controlled trial","volume":"58","author":"Li","year":"2023","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"110467","DOI":"10.1016\/j.jclinane.2021.110467","article-title":"Application of controlled low central venous pressure during hepatectomy: A systematic review and meta-analysis","volume":"75","author":"Liu","year":"2021","journal-title":"J. Clin. Anesth."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"106080","DOI":"10.1016\/j.ijsu.2021.106080","article-title":"Milrinone is better choice for controlled low central venous pressure during hepatectomy: A randomized, controlled trial comparing with nitroglycerin","volume":"94","author":"Yang","year":"2021","journal-title":"Int. J. Surg."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jss.2018.03.022","article-title":"Prolonged operative duration is associated with complications: A systematic review and meta-analysis","volume":"229","author":"Cheng","year":"2018","journal-title":"J. Surg. Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00423-021-02361-z","article-title":"Safety of intermittent Pringle maneuver during minimally invasive liver resection in patients with hepatocellular carcinoma with and without cirrhosis","volume":"407","author":"Haber","year":"2022","journal-title":"Langenbecks Arch. Surg."},{"key":"ref_106","first-page":"3158","article-title":"Hemihepatic versus total hepatic inflow occlusion during hepatectomy: A systematic review and meta-analysis","volume":"17","author":"Wang","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/gutjnl-2014-308513","article-title":"Liver transplantation for hepatocellular carcinoma beyond the Milan criteria","volume":"65","author":"Xu","year":"2016","journal-title":"Gut"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e13254","DOI":"10.1111\/ctr.13254","article-title":"A long-term experience with expansion of Milan criteria for liver transplant recipients","volume":"32","author":"Commander","year":"2018","journal-title":"Clin. Transplant."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/hep.30413","article-title":"Alpha-Fetoprotein Decrease from > 1000 to < 500 ng\/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes","volume":"69","author":"Mehta","year":"2019","journal-title":"Hepatology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1097\/TP.0000000000003174","article-title":"Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference","volume":"104","author":"Mehta","year":"2020","journal-title":"Transplantation"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S1470-2045(20)30224-2","article-title":"Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): A randomised, controlled, phase 2b\/3 trial","volume":"21","author":"Mazzaferro","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jhep.2017.02.022","article-title":"Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis","volume":"67","author":"Sapisochin","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Vitale, A., Scolari, F., Bertacco, A., Gringeri, E., D\u2019Amico, F., Bassi, D., D\u2019Amico, F.E., Angeli, P., Burra, P., and Lai, Q. (2021). Sustained Complete Response after Biological Downstaging in Patients with Hepatocellular Carcinoma: XXL-Like Prioritization for Liver Transplantation or \u201cWait and See\u201d Strategy?. Cancers, 13.","DOI":"10.3390\/cancers13102406"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000521665","article-title":"Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF Trial)","volume":"11","author":"Takayama","year":"2022","journal-title":"Liver Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/j.gastro.2005.04.009","article-title":"A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma","volume":"129","author":"Shiina","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1136\/gutjnl-2016-312629","article-title":"Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: A phase III randomised controlled trial","volume":"66","author":"Yu","year":"2017","journal-title":"Gut"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"945123","DOI":"10.3389\/fonc.2022.945123","article-title":"Novel irreversible electroporation ablation (Nano-knife) versus radiofrequency ablation for the treatment of solid liver tumors: A comparative, randomized, multicenter clinical study","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/22\/5378\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:21:48Z","timestamp":1760131308000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/22\/5378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,12]]},"references-count":117,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["cancers15225378"],"URL":"https:\/\/doi.org\/10.3390\/cancers15225378","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,12]]}}}